Stocks of Venus Concept Inc. (NASDAQ:VERO) traded higher last session on Wall Street, down -3.37% to $0.21.
According to the data, Venus Concept Inc. (NASDAQ:VERO) has 4 analysts covering its stock. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $4.75 and a low of $1.00, we find $1.63. Given the previous closing price of $0.22, this indicates a potential upside of 640.91 percent. VERO stock price is now -46.13% away from the 50-day moving average and -73.76% away from the 200-day moving average. The market capitalization of the company currently stands at $13.92M.
A total of 1 analysts have issued a hold rating and 3 have given it a buy rating. Brokers who have rated the stock have averaged $2.25 as their price target over the next twelve months.
With the price target of $2.50, Stifel recently initiated with Hold rating for Venus Concept Inc. (NASDAQ: VERO). On October 20, 2020, Ladenburg Thalmann recently initiated its ‘Buy’ rating on the stock quoting a target price of $6, while ‘BTIG Research’ rates the stock as ‘Buy’.
In other news, Della Penna Domenic, Chief Financial Officer bought 60,000 shares of the company’s stock on Sep 16. The stock was bought for $35,403 at an average price of $0.59. Upon completion of the transaction, the Chief Financial Officer now directly owns 126,663 shares in the company, valued at $26599.23. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 12, VP, Global HR Georgiadis Anna bought 12,782 shares of the business’s stock. A total of $9,083 was incurred on buying the stock at an average price of $0.71. This leaves the insider owning 12,782 shares of the company worth $2684.22. A total of 1.90% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in VERO stock. A new stake in Venus Concept Inc. shares was purchased by MADRYN SELECT OPPORTUNITIES, LP during the first quarter worth $356,000. CIBC WORLD MARKET INC. invested $15,000 in shares of VERO during the first quarter. In the first quarter, JANE STREET GROUP, LLC acquired a new stake in Venus Concept Inc. valued at approximately $10,000. RENAISSANCE TECHNOLOGIES LLC acquired a new stake in VERO for approximately $8,000. CITADEL ADVISORS LLC purchased a new stake in VERO valued at around $7,000 in the second quarter. In total, there are 49 active investors with 79.20% ownership of the company’s stock.
Thursday’s opening bell rang with an opening price of $0.2200 for Venus Concept Inc. (NASDAQ: VERO). During the past 12 months, Venus Concept Inc. has had a low of $0.20 and a high of $2.21. As of last week, the company has a debt-to-equity ratio of 3.40, a current ratio of 3.10, and a quick ratio of 2.30. The fifty day moving average price for VERO is $0.3935 and a two-hundred day moving average price translates $0.8079 for the stock.
The latest earnings results from Venus Concept Inc. (NASDAQ: VERO) was released for Jun, 2022. According to the Medical Devices Company, earnings per share came in at -$0.16, missing analysts’ expectations of -$0.07 by -0.09. This compares to $0.00 EPS in the same period last year. The net profit margin was -30.00% and return on equity was -106.90% for VERO. The company reported revenue of $27.27 million for the quarter, compared to $25.83 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 5.57 percent. For the current quarter, analysts expect VERO to generate $22.14M in revenue.
Venus Concept Inc.(VERO) Company Profile
Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes aesthetic device platforms, including Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; and Venus Viva, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss, a device for non-invasive lipolysis of the abdomen and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; and ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles. The company is headquartered in Toronto, Canada.